Analysts Set Expectations for TARA FY2029 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Protara Therapeutics in a note issued to investors on Thursday, March 6th. HC Wainwright analyst A. Fein expects that the company will earn ($0.73) per share for the year. HC Wainwright has a "Buy" rating and a $23.00 price target on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share.

A number of other research analysts have also commented on the stock. Lifesci Capital initiated coverage on shares of Protara Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $22.00 price objective on the stock. Guggenheim restated a "buy" rating and issued a $20.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th.

Protara Therapeutics Stock Up 9.3 %

Protara Therapeutics stock traded up $0.35 during trading hours on Friday, hitting $4.10. 188,291 shares of the company traded hands, compared to its average volume of 311,569. The firm's 50-day simple moving average is $4.53 and its two-hundred day simple moving average is $3.44. The firm has a market cap of $84.58 million, a P/E ratio of -1.45 and a beta of 1.69. Protara Therapeutics has a 1-year low of $1.60 and a 1-year high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.09.

Remove Ads

Institutional Trading of Protara Therapeutics

A number of large investors have recently added to or reduced their stakes in TARA. XTX Topco Ltd bought a new position in shares of Protara Therapeutics in the third quarter valued at $60,000. HBK Investments L P acquired a new position in shares of Protara Therapeutics in the 4th quarter worth $106,000. Squarepoint Ops LLC acquired a new stake in shares of Protara Therapeutics during the fourth quarter worth $110,000. Dimensional Fund Advisors LP purchased a new stake in shares of Protara Therapeutics during the fourth quarter valued at $111,000. Finally, Bailard Inc. acquired a new position in shares of Protara Therapeutics in the 4th quarter valued at $157,000. 38.13% of the stock is currently owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.